Last reviewed · How we verify
Spiromax Budesonide/formoterol
Spiromax Budesonide/formoterol is a combination of a corticosteroid and a long-acting beta2-adrenergic receptor agonist used to treat asthma and COPD.
Spiromax Budesonide/formoterol is a combination of a corticosteroid and a long-acting beta2-adrenergic receptor agonist used to treat asthma and COPD. Used for Maintenance and relief of asthma symptoms, Maintenance treatment of COPD.
At a glance
| Generic name | Spiromax Budesonide/formoterol |
|---|---|
| Also known as | Spiromax® budesonide/formoterol |
| Sponsor | University Medical Center Groningen |
| Drug class | Corticosteroid/long-acting beta2-adrenergic receptor agonist |
| Target | Beta2-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Budesonide is a corticosteroid that reduces inflammation in the airways, while formoterol is a long-acting beta2-adrenergic receptor agonist that relaxes bronchial muscles to improve airflow.
Approved indications
- Maintenance and relief of asthma symptoms
- Maintenance treatment of COPD
Common side effects
- Oral thrush
- Headache
- Cough
- Dysphonia
- Muscle cramps
Key clinical trials
- Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma (PHASE3)
- Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER® (PHASE3)
- Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment
- Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD (PHASE3)
- Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD (NA)
- Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spiromax Budesonide/formoterol CI brief — competitive landscape report
- Spiromax Budesonide/formoterol updates RSS · CI watch RSS
- University Medical Center Groningen portfolio CI